Stock Scorecard



Stock Summary for Spero Therapeutics Inc (SPRO) - $1.72 as of 3/29/2024 7:17:53 AM EST

Total Score

22 out of 29

Currently on the following lists
Growth Stock List
Tim's Recommendation
Buy

Growth List Algorithm Criteria for SPRO

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for SPRO

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for SPRO

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for SPRO

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for SPRO

Why Robinhood Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Robinhood Markets ( NASDAQ:HOOD ) 3/14/2024 12:05:00 PM
Spero Therapeutics, Inc. ( SPRO ) Q4 Earnings and Revenues Top Estimates 3/13/2024 9:10:00 PM
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024 - Spero Therapeutics ( NASDAQ:SPRO ) 3/6/2024 1:05:00 PM
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024 3/6/2024 1:05:00 PM
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections 2/28/2024 1:05:00 PM
Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference - Spero Therapeutics ( NASDAQ:SPRO ) 2/26/2024 1:05:00 PM
Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference 2/26/2024 1:05:00 PM
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) 1/31/2024 9:05:00 PM
Urinary Tract Infections ( UTI ) Treatment Market Projection US$ 13.7 Billion by 2030 with a 5.5% CAGR, Persistence Market Research 1/26/2024 8:31:00 AM
Spero Therapeutics Provides Corporate Update and 2024 Outlook 1/5/2024 1:05:00 PM

Financial Details for SPRO

Company Overview

Ticker SPRO
Company Name Spero Therapeutics Inc
Country USA
Description Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multidrug resistant (MDR) bacterial infections and rare diseases in the United States. The company is headquartered in Cambridge, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2023
Next Earnings Date 5/9/2024

Stock Price History

Last Day Price 1.72
Last Day Price Updated 3/29/2024 7:17:53 AM EST
Last Day Volume 154,085
Average Daily Volume 430,432
52-Week High 2.00
52-Week Low 0.99
Last Price to 52 Week Low 73.74%

Valuation Measures

Trailing PE 4.00
Industry PE 100.07
Sector PE 60.76
5-Year Average PE -2.42
Free Cash Flow Ratio 1.21
Industry Free Cash Flow Ratio 12.70
Sector Free Cash Flow Ratio 31.04
Current Ratio Most Recent Quarter 3.53
Total Cash Per Share 1.42
Book Value Per Share Most Recent Quarter 2.02
Price to Book Ratio 0.89
Industry Price to Book Ratio 5.57
Sector Price to Book Ratio 21.66
Price to Sales Ratio Twelve Trailing Months 0.89
Industry Price to Sales Ratio Twelve Trailing Months 13.94
Sector Price to Sales Ratio Twelve Trailing Months 8.77

Share Statistics

Total Shares Outstanding 53,869,000
Market Capitalization 92,654,680
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.02
Current Dividend Amount 0.00
Dividend Aristocrat? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage -2.60%
All-Time Dividend Growth Rate Percentage 2.38%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 75.30%
Annual Earnings Growth 149.15%
Reported EPS 12 Trailing Months 0.43
Reported EPS Past Year 0.52
Reported EPS Prior Year -1.66
Net Income Twelve Trailing Months 22,806,000
Net Income Past Year 22,806,000
Net Income Prior Year -46,400,000
Quarterly Revenue Growth YOY 55.00%
5-Year Revenue Growth 92.11%

Balance Sheet

Total Cash Most Recent Quarter 76,333,000
Total Cash Past Year 76,333,000
Total Cash Prior Year 109,107,000
Net Cash Position Most Recent Quarter 76,246,000
Net Cash Position Past Year 76,246,000
Long Term Debt Past Year 87,000
Long Term Debt Prior Year 96,000
Total Debt Most Recent Quarter 87,000
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 106,894,000
Total Stockholder Equity Prior Year 75,934,000
Total Stockholder Equity Most Recent Quarter 106,894,000

Options

Put/Call Ratio 0.15
Has Options False
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.04
MACD Signal 0.05
20-Day Bollinger Lower Band 1.10
20-Day Bollinger Middle Band 1.47
20-Day Bollinger Upper Band 1.83
Beta 0.55
RSI 56.96
50-Day SMA 1.46
200-Day SMA 7.82

System

Modified 3/29/2024 7:18:40 AM EST